Quick Answer
ImmunityBio, Inc. reported Cash And Cash Equivalents At Carrying Value of $88.33 million for the year ending 2025.
- ImmunityBio, Inc. showed a decrease of -38.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from ImmunityBio, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), ImmunityBio, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 76,050.0%.
- Historical annual values: Fiscal year 2025: $88.33 million | Fiscal year 2024: $143.43 million | Fiscal year 2023: $265.45 million | Fiscal year 2022: $104.64 million | Fiscal year 2021: $181.10 million | Fiscal year 2020: $34.92 million | Fiscal year 2019: $75.80 million | Fiscal year 2018: $16.82 million | Fiscal year 2017: $23.87 million | Fiscal year 2016: $8.08 million | Fiscal year 2015: $175.91 million | Fiscal year 2014: $59.10 million | Fiscal year 2013: $350.0 thousand | Fiscal year 2012: $116.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: